Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig

Diabetes

Volumn 47, Issue 5, 1998, Pages 764-769

  Deacon, Carolyn F ^a   Hughes, Thomas E ^b   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE; GLUCAGON LIKE PEPTIDE 1;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG POTENTIATION; ENZYME DEGRADATION; ENZYME INHIBITION; GLUCOSE HOMEOSTASIS; INSULIN LIKE ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SWINE;

EID: 0031916924     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.5.764     Document Type: Article

References (36)

1. Ørskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701-711, 1992
2. Holst JJ, Nauck MA, Deacon CF, Ørskov C: Potential of GLP-1 in diabetes management. In Glucagon III. Handbook of Experimental Pharmacology. Lefevbre PJ, Ed. Berlin, Springer Verlag, 1996, p. 311-326
3. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet ii:1300-1304, 1987
4. Weir GC, Mojsov S, Hendrick GK, Habener JF: Glucagon-like peptide 1(7-37) actions on endocrine pancreas. Diabetes 38:338-342, 1989
5. Gutniak M, Holst JJ, Ørskov C, Ahrén B, Efendić S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 236:1316-1322, 1992
6. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
7. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
8. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586, 1996
9. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
10. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458-E464, 1996
11. Pridal L, Deacon CF, Kirk O, Christensen JV, Carr RD, Holst JJ: Glucagon-like peptide-1 (7-37) has a larger volume of distribution than glucagon-like peptide-1 (7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. Eur J Drug Metab Pharmacokinet 21:51-59, 1996
12. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
13. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
14. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
15. Knudsen LB, Pridal L: Glucagon-like peptide-1 (9-36)amide is a major metabolite of glucagon-like peptide-1 (7-36)amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435, 1996
16. Pauly RP, Demuth H-U, Rosche F, Schmidt J, White HA, McIntosh CHS, Pedersen RA: Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance (Abstract). Regul Pept 64:148, 1996
17. Balkan B, Kwasnik L, Miserendino R, Mone M, Hughes TE, Li X: Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in obese Zucker rats (Abstract). Diabetologia 40 (Suppl, 1):A131, 1997
18. Li X, Kwasnik L, Miserendino R, Mone M, Hughes TE, Villhauer EB, Balkan B: Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in insulin-resistant rats (Abstract). Diabetes 46 (Suppl. 1):237A, 1997
19. Tumbleson ME (Ed.); Swine in Biomedical Research, Vol 1. New York, Plenum Press, 1986
20. Miller ER, Ullrey DE: The pig as a model for human nutrition. Annu Rev Nutr 7:361-382, 1987
21. Neubert K, Born I, Faust J, Heins J, Barth A, Demuth HU, Rahfeld JU, Steinmetzer T: Verfahren zur Herstellung neuer Inhibitoren der Dipeptidyl Peptidase IV. German Patent Application. Number DD 296 075 A5, 1983
22. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B: Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19:843-848, 1996
23. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans. Diabetes 43:535-539, 1994
24. Ørskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in the plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 87:415-423, 1991
25. Kubota T, Flentke GR, Bachovchin WW, Stollar BD: Involvement of dipeptidylpeptidase IV in an in vivo immune response. Clin Exp Immunol 89:192-197, 1992
26. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU: Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 271:23222-23229, 1996
27. Rachman J, Turner RC: Drugs on the horizon for treatment of type 2 diabetes. Diabet Med 12:467-478, 1995
28. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers: dose-response-relationships. Diabetologia 38:720-725, 1995
29. Deacon CF, Pridal L, Olesen M, Klarskov L, Holst JJ: Dipeptidyl peptidase IV inhibition influences GLP-1 metabolism in vivo (Abstract). Regul Pept 64:30, 1996
30. Rahfeld J, Schierhorn M, Hartrodt B, Neubert K, Heins J: Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim Biophys Acta 1076:314-316, 1991
31. Anderson DM, Elsley FWH: The intravenous glucose tolerance test in the pig. Q J Exp Physiol 55: 104-111, 1970
32. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Gin Invest 93:2263-2206, 1994
33. Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CHS: The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 45:1335-1341, 1996
34. Frohman LA, Downs TR, Heimer EP, Felix AM: Dipeptidylpeptidase IV and trypsin-Like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 83:1533-1540, 1989
35. Medeiros MD, Turner AJ: Post-secretory processing of regulatory peptides: the pancreatic polypeptide family as a model example. Biochimie 76:283-287, 1994
36. Yaron A, Naider F: Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 28:31-81, 1993